Sign up Australia
Proactive Investors - Run By Investors For Investors

HC Wainwright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board

Analyst Raghuram Selvaraju repeated a 'buy' stance and targets A$1.50 for the shares
HC Wainwright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board
Aussie-listed Cynata is a stem cell group

Broker HC Wainwright is bullish on stem cell group Cynata Therapeutics Ltd (ASX:CYP) following encouraging early findings from clinical trials of its CYP-001 treatment for steroid-resistant graft-versus-host disease.

The data safety monitoring board has now recommended that the group's clinical trial progress to a second Cohort of patients.

READ: Cynata Therapeutics wins U.S. patent for stem cell technology

Analyst Raghuram Selvaraju repeated a 'buy' stance and targets A$1.50 for the shares, which is more than double where they are now - at A$0.64 (up 8.47%).

"All eight participants in Cohort A have demonstrated at least a partial response, which is defined as an improvement in the severity of their graft-vs. host disease (GvHD) by at least one grade vs. baseline. In addition, thus far no treatment-related serious adverse events (SAEs) or safety concerns have been observed. Patient enrollment for Cohort B is now open at seven trial sites in the UK and Australia," said the analyst.

In Cohort B, it is planned that a further eight participants would receive two CYP-001 infusions each at a higher dose level - up to a maximum of 200M cells per infusion, the broker added.

View full CYP profile View Profile

Cynata Therapeutics Ltd Timeline

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use